Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

H pylori eradication in idiopathic thrombocytopenic purpura

H pylori eradication is a favorable therapeutic option for H pylori-positive patients with chronic idiopathic thrombocytopenic purpura, reports the American Journal of Gastroenterology.

News image

fiogf49gjkf04

Eradication of Helicobacter pylori is reported to increase the platelet count in some H pylori-positive patients with chronic idiopathic thrombocytopenic purpura.

However, the efficacy of the eradication was quite different according to the previous reports.

To determine whether H pylori infection can contribute to chronic idiopathic thrombocytopenic purpura, Dr Suzuki and colleagues performed a randomized controlled trial.

In addition, the researchers investigated the possible pathogenic mechanisms and predicted the platelet response after eradication of H pylori.

H pylori eradication was achieved in 85% of patients
American Journal of Gastroenterology

The team analyzed several H pylori virulence factors, and the urease activities of the infected H pylori strains.

The research team also analyzed the titers of anti-CagA IgG antibodies in each patient.

The research team reported that patients with chronic idiopathic thrombocytopenic purpura underwent gastroscopy and that gastric H pylori infection was confirmed by culture.

The team randomized H pylori-positive chronic idiopathic thrombocytopenic purpura patients to either the eradication or the non-eradication group.

The eradication group received a standard antibiotic therapy for H pylori.

The researchers defined response to treatment as complete if the platelet count was above 150 to 103/μl.

Partial response to treatment was defined as the platelet count increasing by more than 50 to 103/μl above the pretreatment count.

The team investigated virulence factors by PCR and PCR-based direct sequencing.

The researchers measured anti-CagA IgG antibody titer of each patient's serum by ELISA.

The researchers found that of the 36 patients, 25 were positive for H pylori and eradication was achieved in 85% of these patients.

The platelet response was significantly different between the eradication group and the non-eradication group.

The research team identified no significant differences in clinical factors between the responders and the nonresponders.

The researchers observed that H pylori virulence factors and the urease activity were not associated with the response.

In addition, the team noted that the titers of anti-CagA antibodies in the responders were significantly higher than those in the nonresponders.

Dr Suzuki's team concludes, “H pylori eradication treatment is a favorable therapeutic option for H pylori-positive patients with chronic idiopathic thrombocytopenic purpura.”

“Moreover, an ELISA titer of serum anti-CagA antibody may be a good predictor of platelet recovery.”

“Immunological reaction between platelet and anti-CagA antibodies may have some relation to the pathogenesis of H pylori-positive patients with chronic idiopathic thrombocytopenic purpura.”

Am J Gastroenterol 2005: 100(6): 1265
10 June 2005

Go to top of page Email this page Email this page to a colleague

 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us